Vertex Pharmaceuticals Incorporated (VRTX) Return on Invested Capital (ROIC): 18.12%
Is Vertex Pharmaceuticals Incorporated’s return on invested capital (ROIC) high or low?
Vertex Pharmaceuticals Incorporated's return on invested capital (ROIC) of 18.12% is in line with its 5-year average of 17.51%, around the middle of its 5-year range (2.63%–25.06%).
The return on invested capital (ROIC) for Vertex Pharmaceuticals Incorporated (VRTX) is 18.12% as of Tuesday, June 9, 2026. It is above its 12-month average by 74.65% (10.38%).
VRTX Return on Invested Capital (ROIC) Chart
VRTX Average Return on Invested Capital (ROIC) Chart
VRTX Current vs Average Return on Invested Capital (ROIC) Chart
VRTX Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
18.12%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
10.38%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
14.75%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
17.51%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
7.60%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
-1.85%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
-13.16%
CURRENT VS TTM AVG
+74.65%
CURRENT VS 3Y AVG
+22.85%
CURRENT VS 5Y AVG
+3.49%
CURRENT VS 10Y AVG
+138.36%
CURRENT VS 15Y AVG
+1078.14%
CURRENT VS 20Y AVG
+237.70%
VRTX Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | — | 18.12% | 10.38% | 14.75% | 17.51% |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 13.90% | 13.75% | 11.92% | 10.17% |
| Medtronic plc (MDT) | $105.25B | 0.00% | 3.04% | 3.93% | 4.51% |
| CVS Health Corporation (CVS) | $123.84B | 4.72% | 4.17% | 4.46% | 4.93% |
| Danaher Corporation (DHR) | $133.37B | 5.72% | 5.90% | 6.54% | 6.70% |
| Elevance Health Inc. (ELV) | $92.17B | 6.65% | 6.70% | 7.11% | 7.33% |
| Pfizer Inc. (PFE) | $146.48B | 8.84% | 9.06% | 10.60% | 10.43% |
| Cigna Corporation (CI) | $78.04B | 7.35% | 7.02% | 7.07% | 6.50% |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 13.71% | 12.85% | 12.25% | 11.92% |
| Gilead Sciences, Inc. (GILD) | $155.82B | 21.53% | 11.95% | 11.58% | 9.92% |
Capital Efficiency
ROIC
18.1%
ROE
21.2%
Vertex Pharmaceuticals Incorporated Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Vertex Pharmaceuticals Incorporated Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The return on invested capital (ROIC) for VRTX stock is 18.12%.
- Is Vertex Pharmaceuticals Incorporated's return on invested capital (ROIC) high or low?
- Vertex Pharmaceuticals Incorporated's return on invested capital (ROIC) of 18.12% is in line with its 5-year average of 17.51%, around the middle of its 5-year range (2.63%–25.06%).
- What is the TTM average return on invested capital (ROIC) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The TTM average return on invested capital (ROIC) for VRTX stock is 10.38%.
- What is the 3Y average return on invested capital (ROIC) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 3Y average return on invested capital (ROIC) for VRTX stock is 14.75%.
- What is the 5Y average return on invested capital (ROIC) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 5Y average return on invested capital (ROIC) for VRTX stock is 17.51%.
- What is the 10Y average return on invested capital (ROIC) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 10Y average return on invested capital (ROIC) for VRTX stock is 7.60%.
- What is the 15Y average return on invested capital (ROIC) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 15Y average return on invested capital (ROIC) for VRTX stock is -1.85%.
- What is the 20Y average return on invested capital (ROIC) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 20Y average return on invested capital (ROIC) for VRTX stock is -13.16%.
Vertex Pharmaceuticals Incorporated Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 18.12% |
| 2024-12-31 | 2.63% |
| 2023-12-31 | 16.44% |
| 2022-12-31 | 21.81% |
| 2021-12-31 | 20.99% |
| 2020-12-31 | 25.06% |
| 2019-12-31 | 14.39% |
| 2018-12-31 | 12.38% |
| 2017-12-31 | -26.07% |
| 2016-12-31 | 0.41% |
| 2015-12-31 | -22.54% |
| 2014-12-31 | -34.65% |
| 2013-12-31 | -32.83% |
| 2012-12-31 | 0.10% |
| 2011-12-31 | 4.28% |
| 2010-12-31 | -50.16% |
| 2009-12-31 | -35.36% |
| 2008-12-31 | -56.56% |
| 2007-12-31 | -94.45% |
| 2006-12-31 | -26.93% |
| 2005-12-31 | -33.40% |
| 2004-12-31 | -39.52% |
| 2003-12-31 | -44.83% |
| 2002-12-31 | -14.42% |
| 2001-12-31 | -10.77% |
| 2000-12-31 | -4.58% |
| 1999-12-31 | -18.31% |
| 1998-12-31 | 0.00% |
| 1997-12-31 | 0.00% |
| 1996-12-31 | -21.39% |
Related Metrics
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani